Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LataMed AILMED -5.52%23 3-1 Month Momentum % is 22.93% as of Sep. 02, 2026. GuruFocus rates LMED with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 2,835 Software companies, LataMed AI ranks better than 92.38% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-02), LataMed AI's 3-1 Month Momentum % is 22.93%.
The industry rank for LataMed AI's 3-1 Month Momentum % or its related term are showing as below:
LMED's 3-1 Month Momentum % is ranked better than 92.38% of 2835
companies
in the Software industry
Industry Median: -6.1
vs LMED: 22.93
LataMed AI (OTCPK:LMED) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
LataMed AI 3-1 Month Momentum % Related Terms
LMED vs RYDE, RDZN, DMRC: 3-1 Month Momentum % Comparison
For the Software - Application subindustry, LataMed AI's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LataMed AI 3-1 Month Momentum % vs Software Industry
For the Software industry and Technology sector, LataMed AI's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where LataMed AI's 3-1 Month Momentum % falls into.
LataMed AI (OTCPK:LMED) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LataMed AI (LMED) has a 3-1 Month Momentum % of 22.93% as of Sep. 02, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on LataMed AI and its competitors. According to the industry distribution chart, LataMed AI ranks #216 out of 2835 companies in the Software industry, placing it in the top 7.6%.
Is LataMed AI's 3-1 Month Momentum % too high?
LataMed AI's current 3-1 Month Momentum % is 22.93%. Based on the distribution chart, LataMed AI ranks #216 out of 2835 companies in the Software industry, which is in the top quartile — a strong position relative to peers. Overall, LataMed AI has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does LataMed AI's 3-1 Month Momentum % compare to RYDE and RDZN?
According to the Software industry distribution chart, LataMed AI ranks #216 out of 2835 companies for 3-1 Month Momentum %. This places LataMed AI in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Software company?
A good 3-1 Month Momentum % depends on the Software industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on LataMed AI and its competitors. LataMed AI's current 3-1 Month Momentum % is 22.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LataMed AI stock overvalued right now?
LataMed AI (LMED) has a current 3-1 Month Momentum % of 22.93%. The current 3-1 Month Momentum % is 22.93%. LataMed AI's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For LataMed AI (LMED), the current 3-1 Month Momentum % is 22.93% as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LataMed AI Corp is a technology company focused on the development and deployment of artificial intelligence-driven healthcare solutions across Latin America. Its healthcare platform includes AI-enabled analytics, telehealth infrastructure, and coordinated care systems designed to support healthcare delivery in emerging markets. The company develops digital infrastructure for patient prioritization, clinical workflow management, telehealth access, care coordination, and healthcare system operations. It holds issued patents for its core AI modules-CardioAI, PulmoAI, and NeuroAI-which deliver predictive analytics for cardiovascular, pulmonary, and neurological disease detection and management.
23GF Score
Get the complete analysis for LMED
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMED has been successfully added to your 
